Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19711167 | 0.84 | GRIN2B (0.38) | SLC6A2SLC6A4SLC6A3GRIN2BHRH3 | |
| SCHEMBL13132647 | 0.81 | GRIN2B (0.49) | GRIN2BHSP90AA1HRH3 | |
| SCHEMBL19701929 | 0.80 | BACE1 (0.39) | SLC6A2SLC6A4SLC6A3GRIN2BHRH3 | |
| SCHEMBL13541680 | 0.78 | SLC6A2 (0.65) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL18716730 | 0.77 | KDM4E (0.60) | SLC6A2SLC6A4SLC6A3GRIN2BHRH3 | |
| SCHEMBL25487549 | 0.74 | SLC6A4 (0.50) | SLC6A2SLC6A4SLC6A3GRIN2BHRH3 | |
| SCHEMBL19710803 | 0.73 | SLC6A4 (0.46) | SLC6A2SLC6A4SLC6A3LMNACYP2D6 | |
| SCHEMBL12857 | 0.73 | ALDH1A1 (0.56) | SLC6A2SLC6A4SLC6A3CYP2D6CYP2C9 | |
| SCHEMBL23513906 | 0.71 | ACHE (0.38) | LMNACYP2C9CYP2C19 | |
| SCHEMBL27794052 | 0.71 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3209664-B1 | BICYCLIC HETEROARYL AMINE COMPOUNDS AS PI3K INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-06-03 | — | — | EP | disclosed |
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | PIK3R3, JAK2, JAK3 | SLC6A2 3622/4885SLC6A4 2991/4885SLC6A3 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.